172 results on '"Bruin, Gerard"'
Search Results
2. Chapter 34: A Case Study of Bridging from a Lyophilizate Formulation to an Autoinjector for Patient Self-Administration
3. Chapter 34: A Case Study of Bridging from a Lyophilizate Formulation to an Autoinjector for Patient Self-Administration
4. Advantages of a second ventilation circuit when using a double-lumen endotracheal tube
5. In reply: Use of a second ventilatory circuit when using a double-lumen endotracheal tube
6. AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women
7. 52241 Secukinumab demonstrates low immunogenicity in patients with moderate-to-severe hidradenitis suppurativa: Results from placebo-controlled, double-blind, Phase 3 SUNSHINE and SUNRISE trials
8. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial*
9. Absorption, Distribution, Metabolism, and Excretion of Therapeutic Proteins: Current Industry Practices and Future Perspectives
10. Characterizing the pharmacokinetics and biodistribution of therapeutic proteins: an industry white paper
11. Analysis of Oligonucleotides and Antisense DNA Analogs
12. ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans
13. Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52‐week results from MATURE, a randomized, placebo‐controlled trial
14. Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety
15. L’administration du sécukinumab par un auto-injecteur de 2 mL démontre une efficacité élevée avec une sécurité et une tolérance comparables chez les patients adultes atteints de psoriasis en plaques : résultats à 16 semaines de l’étude MATURE
16. β-Defensin 2 is a responsive biomarker of IL-17A–driven skin pathology in patients with psoriasis
17. 27599 Secukinumab administration by a 2 mL autoinjector demonstrates high efficacy with comparable safety and tolerability in adult patients with plaque psoriasis: 16-week results from MATURE
18. 25482 Secukinumab efficacy and safety profile in pediatric patients with severe chronic plaque psoriasis up to 1 year
19. 27519 Efficacy, pharmacokinetics, and tolerability of subcutaneous secukinumab injections with 2 mL prefilled syringes (300 mg) in adult subjects with moderate to severe plaque psoriasis
20. Secukinumab rapidly reduces markers of both keratinocyte proliferation and skin integrity in psoriasis: 1264
21. Secukinumab, a novel anti–IL-17A antibody, exhibits low immunogenicity in clinical trials and human in vitro assays: 1320
22. High Efficacy, Safety, and Tolerability of Secukinumab Injection with 2 mL Auto-injector (300 Mg) in Adult Patients with Moderate to Severe Plaque Psoriasis: 52-week Results from MATURE, a Randomised, Placebo-controlled Trial
23. Efficacy, pharmacokinetics, and tolerability of subcutaneous secukinumab injections with 2 mL prefilled syringes (300 mg) in adult subjects with moderate to severe plaque psoriasis
24. Secukinumab administration by a 2 mL autoinjector demonstrates high efficacy with comparable safety and tolerability in adult patients with plaque psoriasis: 16-week results from MATURE
25. Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study
26. Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study
27. Thoracoabdominal Aortic Aneurysm Repair: A Prospective Cohort Study of 121 Cases
28. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohnʼs disease: unexpected results of a randomised, double-blind placebo-controlled trial
29. A microplate solid scintillation counter as a radioactivity detector for high performance liquid chromatography in drug metabolism: Validation and applications
30. Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients
31. Use of a Microplate Scintillation Counter as a Radioactivity Detector for Miniaturized Separation Techniques in Drug Metabolism
32. Advantages of a second ventilation circuit when using a double-lumen endotracheal tube
33. Abstracts of lectures and posters pharmaceutical and biomedical analysis meeting
34. Integrated capillary electrophorosis on flexible silicone microdevices: analysis of DNA restriction fragments and detection of single DNA molecules on microchips
35. Hologram-based refractive index detector for capillary electrophoresis: separation of metal ions
36. A cohort study of coagulation parameters and the use of blood products in surgery of the thoracic and thoracoabdominal aorta
37. Kommerell’s diverticulum and aneurysmal right-sided aortic arch: A case report and review of the literature
38. Lung re-inflation after one-lung ventilation for thoracic surgery: importance of clamping the dependent lung
39. Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis
40. Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis
41. 263 Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in patients with psoriatic arthritis and ankylosing spondylitis during a 52week treatment period
42. Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis.
43. Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis
44. Reply
45. Intubating conditions and correct application of cricoid pressure during rapid sequence induction: who should hold the mask?
46. Interleukin-17A blockade with secukinumab results in decreased neutrophil infiltration in psoriasis: minimally-invasive measurement by tape stripping
47. Secukinumab, a novel anti-IL-17A antibody, exhibits low immunogenicity in clinical trials and human in vitro assays
48. Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated by open flow microperfusion
49. On-Line Preconcentration and Separation of Antisense Oligonucleotides by ITP-CE in Dextran-Filled Capillaries
50. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.